SoFi Technologies’ fundamentals point to accelerating earnings and a higher 2026 repricing despite recent equity dilution.
Zubr Capital’s Oleg Khusaenov examines how European venture capital has moved from chasing headline themes to backing ...
Amphastar Pharmaceuticals faces flat growth and margin pressure as it shifts from generics to branded drugs. Learn why AMPH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback